4//SEC Filing
Holveck David 4
Accession 0001209191-11-013034
CIK 0001100962other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 6:41 PM ET
Size
15.1 KB
Accession
0001209191-11-013034
Insider Transaction Report
Form 4
Holveck David
DirectorPresident & CEO
Transactions
- Award
2010 Stock Incentive Plan Stock Options
2011-02-23+161,983→ 161,983 totalExercise: $33.98Exp: 2021-02-23→ Common Stock (161,983 underlying) - Exercise/Conversion
2010 Stock Incentive Plan Restricted Stock Units (RSU)
2011-02-23+51,913→ 51,913 total - Exercise/Conversion
2010 Stock Incentive Plan Performance Shares
2011-02-23+51,913→ 51,913 total
Footnotes (7)
- [F1]Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of Endo Pharmaceuticals Holdings Inc. common stock. These restricted stock units (RSUs) are generally exercisable 25% per year on each of February 23, 2012, February 23, 2013, February 23, 2014 and February 23, 2015. Upon vesting, we consider the underlying RSUs to be expired. Pursuant to the Endo Pharmaceuticals Executive Deferred Compensation Plan, on November 8, 2009, Mr. Holveck elected to defer receipt of all of these RSUs until February 1, 2016.
- [F2]Pursuant to the Endo Pharmaceuticals Executive Deferred Compensation Plan, on November 8, 2009, Mr. Holveck elected to defer receipt of all of these RSUs until February 1, 2016.
- [F3]These securities were granted to Mr. Holveck in consideration of his services as the President & Chief Executive Officer of Endo Pharmaceuticals Holdings Inc.
- [F4]The performance shares vest upon the Company achieving certain financial targets.
- [F5]Represents target quantity of shares issuable. The exact number of shares issuable will be determined on achievement of certain company performance targets over a cumulative 3-year period, as determined by the Compensation Committee of the Board of Directors of Endo Pharmaceuticals Holdings Inc. The executive can earn between 0% and 200% of the target shares.
- [F6]Representing the right to buy shares of common stock, par value $0.01 per share, of Endo Pharmaceuticals Holdings Inc.
- [F7]These stock options are generally exercisable 25% per year on each of February 23, 2012, February 23, 2013, February 23, 2014 and February 23, 2015.
Issuer
ENDO PHARMACEUTICALS HOLDINGS INC
CIK 0001100962
Entity typeother
Related Parties
1- filerCIK 0001429993
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 6:41 PM ET
- Size
- 15.1 KB